Magenta Therapeutics Inc
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The Company's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. It is developing product candidates to be used individually or, in some cases, in combination with each other.
Buy US stocks in Australia starting with MGTA. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in MGTA
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.